Načítá se...
Belatacept Resistant Rejection is Associated with CD28(+) Memory CD8 T cells
Recently newer therapies have been designed to more specifically target rejection in an effort to improve efficacy and limit unwanted toxicity. Belatacept, a CD28-CD80/86 specific reagent is associated with superior patient survival and graft function than traditional therapy but its adoption as a m...
Uloženo v:
| Vydáno v: | Am J Transplant |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5573634/ https://ncbi.nlm.nih.gov/pubmed/28502128 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.14349 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|